39results about How to "Improve oral glucose tolerance" patented technology

The invention relates to the technical field of microorganisms, and discloses bifidobacterium adolescentis and an application thereof. The collection number of the bifidobacterium adolescentis CCFM8630 is CGMCC No.14395. The bifidobacterium adolescentis CCFM8630 has the advantages that the level of neurotransmitter 5-hydroxytryptamine in peripheral blood of rats can be remarkably upgraded by the bifidobacterium adolescentis CCFM8630; the increased level of hormones such as testosterone in the peripheral blood of the rats due to high-glucose and high-fat diet and anomaly of abundance of Blautiaand Turicibacter in intestinal floras of the rats can be recovered; simulated gastrointestinal fluid can be tolerated, the bifidobacterium adolescentis can be quickly colonized in intestinal tracts,accordingly, rat livers with metabolic syndromes, pathological injury of duodenums and increase of the contents of triglyceride and total cholesterol in serum due to the high-glucose and high-fat dietand oral glucose tolerance can be remarkably improved, and the bifidobacterium adolescentis can be used for preventing, relieving or treating metabolic disorder such as the metabolic syndromes, irritable bowel syndromes and psychological illnesses such as anxiety and depression which are related to the metabolic syndromes.

The invention provides a diabetes-specific enteral nutrition multi-polymerization agent. The diabetes-specific enteral nutrition multi-polymerization agent comprises the following energy by weight percentage: 50%-60% of carbohydrates, 10%-15% of proteins and 25%-35% of fat, wherein the energy supply ratio of monounsaturated fatty acids is 10-20%. The invention provides the nutrition multi-polymerization agent with balanced nutrients and low GI (glycemic index) value against the metabolic characteristics of diabetic patients, which can effectively correct metabolic disorders, reduce the islet beta-cell load and delay and reduce the occurrence and development of diabetic complications. The diabetes-specific enteral nutrition multi-polymerization agent provided by the invention is particularly suitable for the diabetic patients, patients with severe symptoms, traumas and surgical stress associated with high blood sugar, and people with decreased sugar tolerance.

The invention discloses bifidobacterium bifidum CCFM1063 and application thereof. The bifidobacterium bifidum CCFM1063 can be rapidly planted in an intestinal tract, fasting blood-glucose and oral glucose tolerance caused by type II diabetes is significantly improved, and the area under the curve for glucose tolerance is reduced; total cholesterol in a serum increased and high-density lipoproteincholesterol reduced caused by the type II diabetes are significantly improved; the condition of insulin resistance caused by the significantly improved is significantly improved; the level of inflammation in type II diabetes liver tissue is significantly improved; pathological injuries of tissue such as pancreas and liver caused by the type II diabetes are significantly improved; the bifidobacterium bifidum CCFM1063 has higher adsorption capacity on perfluoro caprylic acid, and has the capacity of relieving toxicity of the perfluoro caprylic acid; and the constipation condition caused by the type II diabetes is significantly improved and the level of Allobaculum genus in the intestinal tract is improved, and functions of relieving anxiety and depression and colonitis are achieved.

The invention relates to a mactra veneriformis extract which is prepared by the following method of taking the soft body part of the mactra veneriformis as a material, washing and grinding the material, adding water for decoction, filtering, then obtaining water decoction extracting solution, centrifuging the water decoction extracting solution,collecting supernatant fluid, concentrating, cooling, then adding ethanol for precipitating, filtering, obtaining an ethanol precipitate, drying and then obtaining the mactra veneriformis extract; and deproteinizing the mactra veneriformis extract to obtain purified mactra veneriformis extract which has glycemia-reducing, immune adjusting and liver-protecting functions. The invention also discloses the applications of the mactra veneriformis extract on preparation of medicaments or health care products simultaneously.

Provided is a strain CCFM8630 of Bifidobacterium adolescentis and use thereof. The strain CCFM8630 of Bifidobacterium adolescentis can significantly increase neurotransmitter 5-hydroxytryptamine level in peripheral blood of rat, recover the hormone levels, for example testosterone and so on in peripheral blood of rat, normalize abnormal abundances of Bifidobacterium genus, Blautia genus and Turicibacter genus in intestinal flora of rat affected by high-fat high-starch diet, show pretty good tolerance to simulated gastrointestinal fluid and quickly colonize in intestinal, significantly improve pathological damages of tissues such as liver, duodenum and so on, and increase triglyceride and total cholesterol levels in serum and oral glucose tolerance of rat with metabolic syndrome caused by high-fat high-starch diet. The strain CCFM8630 of Bifidobacterium adolescentis can be used for preventing, relieving or treating metabolic disorder, such as metabolic syndrome, irritable bowel syndrome and mental diseases related to metabolic syndrome such as anxiety, depression and so on.

The invention discloses application of bifidobacterium adolescentis CCFM1061 in preparation of functional microbial agents, foods and / or medicines. The bifidobacterium adolescentis CCFM1061 can be rapidly colonized in the intestinal tracts, can remarkably improve fasting blood glucose and oral glucose tolerance of type 2 diabetes induced by STZ and high-fat diet and decrease the area under a curvewhen glucose tolerance is reduced, can remarkably alleviate the increase of total cholesterol and the decrease of high-density lipoprotein cholesterol in serum of the type 2 diabetes caused by STZ and high-fat diet, can remarkably alleviate the insulin resistance of the type 2 diabetes, can remarkably improve the level of inflammation in liver tissues of the type 2 diabetes, and can remarkably alleviate the pathological damage of the pancreas, liver and other tissues of the type 2 diabetes. In addition, the bifidobacterium adolescentis CCFM1061 has strong adsorption capacity on perfluorooctanoic acid (PFOA), and has the capacity of relieving PFOA toxicity.

The invention discloses a phenoxyacetic acid derivative, a preparation process thereof and use thereof as medicaments, and provides a compound shown as formula (I) and a physiologically acceptable salt thereof, wherein the symbols are as defined in the specification. The compound or physiologically acceptable salt thereofhas GPR40 (G-protein-coupled receptor) regulation function, can cause increase in insulin release, and is useful to be used as an insulin secretagogue or medicaments for prevention or treatment of diabetes and the like.

The invention relates to a novel nitrogen-containing heterocyclic derivative shown as a general formula (I) (please see the formula in the description) and a preparation method thereof and application of a pharmaceutical composition containing the derivative in preparation of a drug for treating diabetes and a metabolic syndrome. The nitrogen-containing heterocyclic derivative has the excellent in-vivo hypoglycemic activity and can be used for preventing or treating the diabetes.

The invention discloses a collagen zymolyte with a blood sugar reducing effect and a preparation method and application thereof, the zymolyte contains Gly-Pro-type peptide composed of 4-7 amino acid residues, and the mass ratio is 30-45%; the general formula of the sequence of the Gly-Pro-type peptide consisting of 4 to 7 amino acid residues is Gly-Pro-Xaa1-Gly-[Xaa2] r-[Xaa3] s-[Gly] t. According to the preparation method provided by the invention, the zymolyte with strong DPP-IV inhibition activity is prepared for the first time, and the DPP-IV inhibition rate of the zymolyte is as high as 68% when the final concentration is 1mg / mL; the zymolyte is rich in Gly-Pro-type peptide composed of 4-7 amino acid residues, and the peptide yield is as high as 45%; animal experiments prove that the zymolyte can regulate fasting blood-glucose of rats with type 2 diabetes mellitus and improve the oral glucose tolerance of the rats with type 2 diabetes mellitus.

The invention relates to the technical field of microorganisms, and discloses a lactobacillus reuteri and its application. The preservation number of Lactobacillus reuteri CCFM8631 of the present invention is CGMCC No.14394, which can significantly improve the level of rat peripheral blood neurotransmitter 5-serotonin; restore the rat peripheral blood testosterone hormone level caused by a high-sugar and high-fat diet and the abnormal abundance of Blautia, Turicibacter, Oscillospira and Bifidobacterium in the intestinal flora; tolerance to simulated gastrointestinal fluid, rapid colonization in the intestinal tract, significantly improved the liver of rats with metabolic syndrome caused by high-sugar and high-fat diet , pathological damage of the duodenum and elevated levels of triglyceride and total cholesterol in serum, used to prevent, slow down or treat metabolic disorders such as metabolic syndrome, irritable bowel syndrome and anxiety and depression related to metabolic syndrome and other mental illness.

The invention relates to uses of compounds shown as a general formula I, stereisomers thereof or medicinal salts of the compounds in preparation of medicines used for treating diabetes mellitus, or in preparation of medicines for preventing or treating diabetic complications, or in preparation of medicines adopted as euglycemic agents.

The invention relates to novel phenoxyacetic acid derivatives disclosed as general formula (I) and a preparation method thereof, and application of a pharmaceutical composition containing the derivatives for preparing a drug for treating diabetes and metabolic syndrome. The phenoxyacetic acid derivatives have excellent in-vivo activity for lowering blood sugar, and can be used for preventing or treating diabetes.

The invention relates to a ginsenoside Rb3 composition and an application thereof in preparing a medicament for treating diabetes. The ginsenoside Rb3 composition is prepared from ginsenoside Rb3 as a main component and 1-5 of a carrier, an excipient, a sweetening agent, an adhesive, a flavoring agent, a preservative, a dispersing agent, a surfactant and a colorant as adjuvants, and the medicament is prepared into tablets, pills, granules, capsules and powder. The method for extracting the ginsenoside Rb3 comprises the following steps: dissolving crude extracts of stems and leaves of American ginseng, ginseng or pseudo-ginseng in water, then separating by NKA-12 macroporous resin, and performing gradient elution by ethanol water to obtain panaxatriol saponin and panaxadiol saponin. Repeated chromatography is preformed on the panaxadiol saponin by silicagel columns to obtain pure ginsenoside Rb3 with the purity of 98%. Proven by animal experiments, the ginsenoside Rb3 has notable effects of symptom improvement and treatment on diabetes and adiposis.

The invention belongs to the field of medicines and health-care products, and particularly discloses composite polysaccharide, a preparation method thereof and application thereof to products for clearing damp, tonifying spleen, reducing fat and losing weight. The composite polysaccharide is prepared from mangnolia officinalis, rhizoma atractylodis macrocephalae, dried orange peel, cortex lycii radicis and black mulberry. The preparation method of the composite polysaccharide comprises water extraction and alcohol precipitation. The composite polysaccharide provided by the invention can obviously reduce body mass increasing rate of a nutritional obesity rat model and retard increment of body weight and Lee's index, can reduce fat mass, fat body ratio and fat cell number, reduce accumulation of internal fat, reduce triglyceride and total cholesterol, adjust high-density lipoprotein and high-density lipoprotein, improve hyperlipidemia, reduce fasting blood glucose, improve oral glucose tolerance and improve the appearance condition and the mental outlook of the nutritional obesity rat, has the effect which is obviously excellent than that of each single polysaccharide component, andcan be used for preparing the medicines or health-care food with effects of clearing damp, tonifying spleen, reducing fat and losing weight.

The invention provides floccularia luteovirens polysaccharide as well as a preparation method thereof and a medical use thereof in controlling diabetes. Crude polysaccharide obtained by water extraction and alcohol precipitation of floccularia luteovirens is subjected to protein removal to obtain any one or more of floccularia luteovirens total sugar, floccularia luteovirens protein composite, floccularia luteovirens polysaccharide or purified homogeneous polysaccharide component. According to the animal experiment, the floccularia luteovirens polysaccharide can reduce bodyweight growth speedof a db / db mouse, reduces fasting blood-glucose of a diabetic mouse, improves oral glucose tolerance, and has good activity of reducing blood fat, resisting oxidization and resisting inflammation. Thefloccularia luteovirens polysaccharide is taken as a natural product obtained from an edible and medicinal fungus resource, is small in toxic and side effect, has remarkable effects of resisting oxidative stress and inflammation, realizing the effects of resisting type 2 diabetes and renal complications, further can be used for developing medicines and healthcare products for safely and effectively preventing, alleviating or treating type 2 diabetes and renal complications caused by diabetes, and has an extremely high edible value, an extremely high medical value and an extremely high economical value.

The present invention concerns a novel function of N-acetylchitobiose and an application of N-acetylchitobiose in health care food. The N-acetylchitobiose is a degradation product of chitin, and is an oligosaccharide which is formed by the binding of two N-acetylglucosamine molecules through a glucosidic bond. Animal tests indicate that the N-acetylchitobiose has obvious inhibiting activity on alpha-glucosidase, and the IC50 of the N-acetylchitobiose is 2.0 mg / ml. The N-acetylchitobiose can significantly reduce the fasting glucose levels of mice with type II diabetes to a minimum value of 6.1 mg / ml. The minimum value of 6.1 mg / ml is significantly lower than the fasting glucose value of 7.9 mg / ml in an acarbose control group, and is close to the upper limit of a fasting blood glucose range in normal healthy mice. Secondly, compared to acarbose, the N-acetylchitobiose can significantly reduce serum blood lipid contents and inhibit the levels of lipid-peroxidation in pancreas. In addition, the N-acetylchitobiose can stabilize the weight of diabetic mice. The combination of the N-acetylchitobiose and xylo-oligosaccharide has obvious hypoglycemic effects as well. The N-acetylchitobiose provided by the invention has good hypoglycemic effects, and can be employed to develop safe and effective health care food which prevents and improves type II diabetes.

The invention relates to a mactra veneriformis extract which is prepared by the following method of taking the soft body part of the mactra veneriformis as a material, washing and grinding the material, adding water for decoction, filtering, then obtaining water decoction extracting solution, centrifuging the water decoction extracting solution,collecting supernatant fluid, concentrating, cooling,then adding ethanol for precipitating, filtering, obtaining an ethanol precipitate, drying and then obtaining the mactra veneriformis extract; and deproteinizing the mactra veneriformis extract to obtain purified mactra veneriformis extract which has glycemia-reducing, immune adjusting and liver-protecting functions. The invention also discloses the applications of the mactra veneriformis extracton preparation of medicaments or health care products simultaneously.

The invention provides floccularia luteovirens polysaccharide as well as a preparation method thereof and a medical use thereof in controlling diabetes. Crude polysaccharide obtained by water extraction and alcohol precipitation of floccularia luteovirens is subjected to protein removal to obtain any one or more of floccularia luteovirens total sugar, floccularia luteovirens protein composite, floccularia luteovirens polysaccharide or purified homogeneous polysaccharide component. According to the animal experiment, the floccularia luteovirens polysaccharide can reduce bodyweight growth speedof a db / db mouse, reduces fasting blood-glucose of a diabetic mouse, improves oral glucose tolerance, and has good activity of reducing blood fat, resisting oxidization and resisting inflammation. Thefloccularia luteovirens polysaccharide is taken as a natural product obtained from an edible and medicinal fungus resource, is small in toxic and side effect, has remarkable effects of resisting oxidative stress and inflammation, realizing the effects of resisting type 2 diabetes and renal complications, further can be used for developing medicines and healthcare products for safely and effectively preventing, alleviating or treating type 2 diabetes and renal complications caused by diabetes, and has an extremely high edible value, an extremely high medical value and an extremely high economical value.

The invention discloses the application of Bifidobacterium adolescentis CCFM1061 in the preparation of functional bacterial agents, foods and or medicines. Bifidobacterium adolescentis CCFM1061 can quickly colonize the intestinal tract and significantly improve the risk of type 2 diabetes induced by STZ and high-fat diet. Fasting blood glucose, oral glucose tolerance, reduce the area under the curve of glucose tolerance; significantly improve the increase of total cholesterol in serum and the decrease of high-density lipoprotein cholesterol in type 2 diabetes caused by STZ and high-fat diet; can significantly improve insulin in type 2 diabetes Resistance; can significantly improve the level of inflammation in type 2 diabetes liver tissue; significantly improve the pathological damage of type 2 diabetes pancreas, liver and other tissues. In addition, Bifidobacterium adolescentis CCFM1061 has a strong adsorption capacity for perfluorooctanoic acid (PFOA), and has the ability to alleviate the toxicity of PFOA.

The invention discloses lactobacillus plantarum SHY130 which is preserved in the China Center for Type Culture Collection (CCTCC), and the preservation number is CCTCC NO: M 2021372. The invention discloses a microbial agent. An active component of the microbial agent comprises the lactobacillus plantarum SHY130. The invention further discloses application of the lactobacillus plantarum SHY130 or the microbial agent in preparation of products for preventing and / or relieving and / or treating diabetes. The invention also provides application of the lactobacillus plantarum SHY130 in preparation of foods, food additives, health care products or medicines as functional probiotics. According to the lactobacillus plantarum SHY130 and the application thereof, an action mechanism of the probiotics on regulating an intestinal island axis is explored, the application range of the lactobacillus plantarum SHY130 is expanded, the utilization value of the lactobacillus plantarum SHY130 is improved, and a new hope is brought to treatment of type II diabetes.

The invention discloses Bifidobacterium bifidum CCFM1063 and its application. Bifidobacterium bifidum CCFM1063 can quickly colonize the intestinal tract, significantly improve fasting blood sugar and oral glucose tolerance caused by type 2 diabetes, and reduce the area under the curve of glucose tolerance; Significantly improve the increase of total cholesterol and decrease of high-density lipoprotein cholesterol caused by type 2 diabetes; significantly improve the insulin resistance caused by type 2 diabetes; significantly improve the level of inflammation in liver tissue of type 2 diabetes; significantly improve the level of inflammation caused by type 2 diabetes Bifidobacterium bifidum CCFM1063 has a strong adsorption capacity for perfluorooctanoic acid, and has the ability to alleviate the toxicity of perfluorooctanoic acid; it can significantly improve the constipation caused by type 2 diabetes and increase the level of Allobaculum in the intestine , has the effect of relieving anxiety, depression and colitis.

The present invention relates to a novel phenoxyacetic acid derivative represented by the general formula (I), preparation method thereof and use of a pharmaceutical composition containing the derivative in preparing a medicament for treating diabetes and metabolic syndrome. The phenoxyacetic acid derivatives have excellent in vivo hypoglycemic activity, which can be used for preventing or treating diabetes.

The invention relates to a novel oxime ether derivative shown as a general formula (I) (please see the formula in the description) and a preparation method thereof and application of a pharmaceutical composition containing the derivative in preparation of a drug for treating diabetes and a metabolic syndrome. The oxime ether derivative has the excellent in-vivo hypoglycemic activity and can be used for preventing or treating the diabetes.

The present invention provides a compound represented by formula I or a pharmaceutically acceptable salt, hydrate or solvate thereof. The present invention also provides new applications of the above compounds or pharmaceutically acceptable salts, hydrates or solvates thereof. The deuterated compound prepared by the present invention can obviously improve the body weight, fasting blood sugar, transaminase and fasting serum insulin of obese patients, improve insulin sensitivity, improve blood lipid index and oral glucose tolerance; this type of compound has good absorption in vivo, high bioavailability, and has It is conducive to the exertion of the drug effect, and the half-life is prolonged, which can reduce the number of administrations, reduce the toxic and side effects, and provide a safe and reliable new choice for clinical drug use. Formula I.

The present invention discloses an application of narrow-range chitosan oligosaccharide in a preparation of functional food for preventing hyperglycemia induced by a long-term high-fat diet. Functionsof the narrow-range chitosan oligosaccharide for preventing the hyperglycemia manifest as a reduction of fasting blood glucose. At the same time, the narrow-range chitosan oligosaccharide also improves oral glucose resistance and insulin resistance induced by the high-fat diet, increases insulin secretion and insulin sensitivity, reduces insulin resistance indexes, alleviates liver tissue fatty degeneration, and restores pancreatic tissue structures. Due to the fact that the used chitosan oligosaccharide is relatively concentrated in molecular weight distribution, a mechanism of a hypoglycemic effect is clearer. By improving excessive gluconeogenesis caused by the high-fat diet, the narrow-range chitosan oligosaccharide promotes glucose transport in muscle tissues and thereby exerts hypoglycemic effects. The used narrow-range chitosan oligosaccharide is developed into the functional food for assisting sugar-lowering and at the same time also provides strong research foundation for theapplication of the chitosan oligosaccharide in assisting the sugar-lowering.

The present invention is the new function of chitobiose and its application in health food. The chitobiose is a degradation product of chitin, and is an oligosaccharide formed by connecting two N-acetylglucosamines with glycosidic bonds. Animal experiments show that the chitobiose has obvious α-glucosidase inhibitory activity, and its IC50 is 2.0mg / mL, which can significantly reduce the fasting blood glucose level of type II diabetic mice, the lowest to 6.1mg / mL, which is significantly lower than The fasting blood glucose value of the control acarbose group was 7.9mg / mL, which was close to the upper limit of the fasting blood glucose value range of normal healthy mice. Second, compared with acarbose, chitobiose can significantly reduce serum lipid levels and inhibit pancreatic lipid peroxidation. In addition, chitobiose can stabilize the body weight of diabetic mice. The compound of chitobiose and xylooligosaccharide also has obvious hypoglycemic effect. The chitobiose of the present invention has a good hypoglycemic effect, and can be used to develop a safe and effective health food for preventing and improving type II diabetes.

The invention discloses tuna roe dipeptidyl peptidase IV (DPP-IV) inhibition oligopeptide and application thereof. The amino acid sequence of the DPP-IV inhibition oligopeptide is Glu-Ile-Pro-Gly-Thr-Arg-Gly-Pro-Leu, and the molecular weight of the DPP-IV inhibition oligopeptide is 939.07 Da. The prepared tuna roe DPP-IV inhibition oligopeptide can significantly inhibit the activity of DPP-IV, reduce the postprandial blood sugar level of a model mouse, improve the oral glucose tolerance and maltose tolerance of the mouse and reduce the content of triglyceride (TG) and cholesterol (TC) of the model mouse, and is safe and free of toxic and side effects; and the tuna roe DPP-IV inhibition oligopeptide can be applied to preparation of food, health-care products and medicines with special medical purposes for treatment or adjuvant treatment of diabetes mellitus type 2 (T2DM).

The invention relates to a preparation method of berberine derivative-alcohol form berberine which includes the following steps: the raw materials of berberine hydrogen sulfate are dissolved in water to prepare the saturated solution of berberine hydrogen sulfate; alkaline solution is dropped in the saturated solution of berberine hydrogen sulfate till no generation of the sediment so as to form the turbid solution; the turbid solution is filtered to get the sediments; all the sediments are dissolved in the organic solvent and are carried out the silica gel column chromatography and elution by organic solvent; the crude product can be obtained by concentration under the reduced pressure of the organic solvent elution solution and vacuum low-temperature drying; the obtained crude product is carried out the recrystallization by using methanol or ethanol so as to get enough amount of berberine derivative pure product. The animal experiments find that the prepared berberine derivative has a variety of pharmaceutical activities and shows the great function of regulating the blood glucose and blood lipids of the rats with the type 2 diabetes, compared with the currently recognized berberine hydrochloride compounds which have the function of regulating the blood glucose and blood lipids and the most relevant structure, the efficacy is much better and the effective dose is much less.

The invention discloses an application of 5 '-methylthioadenosine in preparation of obesity inhibition drugs or health care products, and animal experiments prove that 5'-methylthioadenosine has an obvious inhibition effect on obesity and has a good application prospect in preparation of the obesity inhibition drugs or health care products.